Cui WT, Xue HR, Wei DF, Feng XY, Wang K. Prospects of elafibranor in treating alcohol-associated liver diseases. World J Gastroenterol 2025; 31(2): 99549 [PMID: 39811505 DOI: 10.3748/wjg.v31.i2.99549]
Corresponding Author of This Article
Wei-Tong Cui, MD, Professor, School of Basic Medicine, Qilu Medical University, No. 1678 West Renmin Road, Zibo 255300, Shandong Province, China. klnr727@qlmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2025; 31(2): 99549 Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.99549
Prospects of elafibranor in treating alcohol-associated liver diseases
Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng, Kai Wang
Wei-Tong Cui, Dian-Fang Wei, Xiao-Yu Feng, Kai Wang, School of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China
Hua-Ru Xue, School of Medical Imaging, Qilu Medical University, Zibo 255300, Shandong Province, China
Co-first authors: Wei-Tong Cui and Hua-Ru Xue.
Author contributions: Cui WT designed the research study; Xue HR and Wang K contributed to the search and analysis of the literatures; Cui WT and Xue HR drafted the manuscript, they contributed equally to this manuscript and as co-first authors; Wei DF and Feng XY helped in reviewing and editing of the manuscript; and all the authors have read and approved the final manuscript.
Supported by Natural Science Foundation of Shandong Province, China, No. ZR2019PC053; and the Projects of Medical and Health Technology Development Program in Shandong Province, China, No. 202202020837 and No. 202301040472.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Tong Cui, MD, Professor, School of Basic Medicine, Qilu Medical University, No. 1678 West Renmin Road, Zibo 255300, Shandong Province, China. klnr727@qlmu.edu.cn
Received: July 24, 2024 Revised: October 8, 2024 Accepted: November 25, 2024 Published online: January 14, 2025 Processing time: 146 Days and 14 Hours
Core Tip
Core Tip: Elafibranor is an oral dual peroxisome proliferator-activated receptor α/δ agonist that has demonstrated efficacy in improving hepatic steatosis and inhibiting inflammation and fibrosis associated with nonalcoholic liver diseases. Alcohol-related liver disease (ALD), resulting from excessive alcohol consumption, also presents symptoms such as hepatic steatosis, inflammation, and fibrosis. However, the effectiveness of elafibranor in treating ALD remains unclear. A recent study by Koizumi et al revealed that elafibranor significantly reduced hepatic steatosis, apoptosis, and fibrosis in a mouse model of ALD. Despite the potential of elafibranor for ALD treatment appears promising, further experimental investigations and clinical trials are warranted.
